← Leaderboards
Philip M Spanheimer
Univ Of North Carolina Chapel Hill
$1,206,886
Attributed
$1,804,694
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $807.8K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,804,694 · 2
By mechanism
R37$1,195,616 · 1
K08$609,078 · 1
Top collaborators
- Jose P. Leone2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Soumya Rahima Benhabbour$11,411,217
- Corbin D Jones$5,254,232
- Sophie Charlotte Bendrath$117,821
- Tess Thompson$1,001,816
- Louise Henderson$9,735,205
Others in their field
Other Rising Stars on “Resistance”
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
- Chris Maxwell · National Institute Of Allergy And Infectious Diseases$12,000,000
- Andrew Tomaras · Forge Therapeutics, Inc.$10,977,909
- Christine W Hockett · Avera Mckennan$8,908,366
Research focus
ResistanceTumorInhibitorPromoterTamoxifenTreatment ResponseEstrogen ReceptorsImproved OutcomeMammary NeoplasmsPreclinical EfficacyResponse BiomarkerSignal PathwayTargeted TreatmentTherapeutic TargetEndocrineErbb2 GeneBiological MarkersHormone TherapyKnock-DownMalignant Breast NeoplasmClinical TrialsOrganoidsResponseWoman
Grant awards (5)
Predicting Endocrine Therapy Response In Male Breast Tumors$590,870
R37 · FY2025 · CA · contact PI
Repurposing RET Inhibitors for Endocrine Resistant Breast Cancer$203,026
K08 · FY2025 · CA · contact PI
Predicting Endocrine Therapy Response In Male Breast Tumors$604,746
R37 · FY2024 · CA · contact PI
Repurposing RET Inhibitors for Endocrine Resistant Breast Cancer$203,026
K08 · FY2024 · CA · contact PI
Repurposing RET Inhibitors for Endocrine Resistant Breast Cancer$203,026
K08 · FY2023 · CA · contact PI